Dr. Reddy's Laboratories Ltd (DRL), the country's second largest drug maker, has tied up with Hetero Drugs to sell the generic Sofosbuvir tablets (400mg) in India. The drug will make a significant difference in the diagnosis and treatment of Hepatitis C.
"The launch of Resof is in line with Dr Reddy's philosophy of offering 'innovative medicine at an affordable price' and will provide significant relief to patients, resulting in potential cure and a high barrier to resistance at an affordable price for those living with Hepatitis C," said G.V. Prasad, Co-chairman, DRL.
The Drug Controller General of India approved the drug for manufacture and marketing. "Clinical studies have indicated that Sofosbuvir 400 mg, in combination with other agents, achieved very high cure rates, while shortening the duration of the treatment to as little as 12 weeks and reducing or completely eliminating the need for interferon injections, depending on the viral genotype," said DRL.
DRL has a non-exclusive licence agreement with Gilead Sciences to manufacture and sell generic versions of its chronic Hepatitis C medicines in 91 developing countries.